Volume 6.14 | Apr 15

Mesenchymal Cell News 6.14 April 15, 2014
Mesenchymal Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mesenchymal Cell News on Twitter
 
TOP STORY
Proper Stem Cell Function Requires Hydrogen Sulfide
Stem cells in bone marrow need to produce hydrogen sulfide in order to properly multiply and form bone tissue, according to a new study. [Press release from Ostrow School of Dentistry, University of Southern California discussing online prepublication in Cell Stem Cell] Press Release | Abstract | Graphical Abstract
Enter to Win a Travel Award to ISSCR 2014
 
PUBLICATIONS (Ranked by impact factor of the journal)
Cell Isolation Induces Fate Changes of Bone Marrow Mesenchymal Cells Leading to Loss or Alternatively to Acquisition of New Differentiation Potentials
Scientists showed that mesenchymal cells, a priori exhibiting a limited differentiation potential, may gain new capacities and become multipotent following single cell isolation. [Stem Cells] Abstract

In Vivo Osteogenic Differentiation of Human Turbinate Mesenchymal Stem Cells in an Injectable In Situ-Forming Hydrogel
Human turbinate mesenchymal stromal cells (hTMSCs) showed positive expression of mesenchymal stem cell markers and proliferated at a high rate. hTMSCs exhibited osteogenic differentiation in vitro in the presence of osteogenic factors. [Biomaterials] Abstract

Interleukin-6 Induces the Lineage Commitment of Bone Marrow-Derived Mesenchymal Multipotent Cells through Down-Regulation of Sox2 by Osteogenic Transcription Factors
Researchers aimed to identify mechanisms by which cell-cell interactions between heterogeneous bone marrow-derived mesenchymal stromal cells affect stemness and lineage commitment of multipotent subpopulation. [FASEB J] Abstract

Amniotic Mesenchymal Stem Cells Display Neurovascular Tropism and Aid in the Recovery of Injured Peripheral Nerves
Researchers determined whether local injection of amniotic membrane-derived mesenchymal stem cells (AMMs) ameliorates peripheral neuropathy. AMMs were transplanted into injured sciatic nerves. AMM injection promoted significant recovery of motor nerve conduction velocity and voltage amplitude compared to human adipose-derived mesenchymal stem cells. [J Cell Mol Med] Abstract

Adipose-Derived Regenerative Cells in Patients with Ischemic Cardiomyopathy: The PRECISE Trial
Researchers performed the first randomized, placebo-controlled, double-blind trial to examine the safety and feasibility of the transendocardial injections of adipose-derived regenerative cells in no-option patients with ischemic cardiomyopathy. [Am Heart J] Abstract | Press Release

Characterization of Constitutive Promoters for piggyBac Transposon-Mediated Stable Transgene Expression in Mesenchymal Stem Cells (MSCs)
Researchers used the piggyBac transposon system and conducted a systematic comparison of six commonly-used constitutive promoters for their abilities to drive RFP or firefly luciferase expression in somatic HEK-293 cells and MSC iMEF cells. [PLoS One] Full Article

Characteristics of c-Kit+ Progenitor Cells in Explanted Human Hearts
Researchers isolated and characterized c-Kit+ progenitor cells from explanted human hearts. Isolated c-Kit+ cells display mesenchymal stem cell features and are thought to differentiate into endothelial cells. [Clin Res Cardiol] Full Article

Placental Mesenchymal Stem Cells of Fetal and Maternal Origins Demonstrate Different Therapeutic Potentials
Scientists investigated the differences in human placental mesenchymal stem cells of fetal and maternal origins in the aspects of clinical importance. [Stem Cell Res Ther] Abstract | Full Article

In Vitro Biosafety Profile Evaluation of Multipotent Mesenchymal Stem Cells Derived from the Bone Marrow of Sarcoma Patients
To investigate the possible oncogenic potential of mesenchymal stem cells (MSCs) from osteosarcoma or Ewing sarcoma patients (MSC-SAR) after expansion, scientists focused on a biosafety assessment of MSC-SAR obtained after short- and long-term cultivation compared with MSCs from healthy donors. [J Transl Med] Abstract | Full Article

Generation of High-Yield Insulin Producing Cells from Human Bone Marrow Mesenchymal Stem Cells
Scientists described a stage specific differentiation protocol for the generation of insulin producing islet-like clusters from human bone marrow mesenchymal stem cells. [Mol Biol Rep] Abstract

Down-Regulation of Sox11 Is Required for Efficient Osteogenic Differentiation of Adipose-Derived Stem Cells
Scientists performed a microarray-based gene expression profiling of osteogenic differentiation and found that the transcription factor Sox11 is down-regulated during the process. [Mol Cells] Abstract

Request Your Free Wallchart: Mesenchymal Stem Cells (A Nature Reviews Molecular Cell Biology Collaboration)
 
REVIEWS
Distinct VEGF Functions during Bone Development and Homeostasis
It is well known that vascular endothelial growth factor-A (VEGF) is required for effective coupling of angiogenesis to endochondral and membranous bone formation during skeletal development. However, less well known are the roles of VEGF in regulating the differentiation and/or functions of skeletal cells such as chondrocytes, osteoblasts, and osteoclasts. The authors discuss some of these functions. [Arch Immunol Ther Exp] Abstract

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.
 
INDUSTRY NEWS
Regeneus Receives Ethics Approval for Collecting Stem Cells from Human Donors for First-in-Man Safety Trial of Its Off-the-Shelf Treatment for Osteoarthritis
Regeneus announced that it has received ethics approval to collect stem cells from human donors for use in production of its new allogeneic off-the-shelf stem cell product for osteoarthritis (OA). This approval allows Regeneus to begin manufacturing the cells for its first-in-man clinical trial to assess initial safety and preliminary efficacy in human volunteers with knee OA. [Regeneus Ltd] Press Release

Stem Cells for Spine: Phase II Outcomes Promising for Mesoblast
Mesoblast recently completed enrollment for its double-blind, placebo-controlled Phase II clinical trial at multiple sites across the United States and Australia to randomize 100 patients with intervertebral disc disease to receive either high doses of the company’s allogeneic MPCs with hyaluronic acid carrier, hyaluronic acid carrier alone or saline solution. [Becker’s Spine Review] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
 
POLICY NEWS
NIH Stem-Cell Program Closes
Stem-cell researchers at the US National Institutes of Health (NIH) have been left frustrated and confused following the demise of the agency’s Center for Regenerative Medicine. [Nature News] Editorial

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 10th Swiss Stem Cells Network (SSCN) Annual Meeting
June 4, 2014
Geneva, Switzerland

Visit our events page to see a complete list of events in the mesenchymal cell community.
 
JOB OPPORTUNITIES
NEW Research Associate / Adjunct – Mesenchymal Stem Cells (Nicolaus Copernicus University)

NEW Postdoctoral Fellowship – Hematology, Immunology, Cancer Therapeutics (Nationwide Children’s Hospital)

Postdoctoral Position – Intestinal Immunology (Biomedical Sciences Research Center “Alexander Fleming”)

Postdoctoral Fellow – Regenerative Medicine (University of California, San Francisco)

Postdoctoral Position – Cardiopulmonary Molecular Biology (Hannover Medical School)

Postdoctoral Associate – Cardiac Repair Mechanisms of Mesenchymal Stem Cells and Cardiac Stem Cells (University of Miami)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Mesenchymal Cell News: Archives | Events | Contact Us